Cubist Pharm: (NASD: CBST)
$49.51
0.88 (1.81%)
Volume 976,265
May 17 04:00 PM ET
Zacks Rank: 2-Buy 
| #2 |
Overview Quote
Stock Activity
| Day Low - High | 48.35 - 49.62 |
| 52wk Low - High | 36.73 - 49.86 |
| Previous Close | 48.63 |
| Avg. Volume | 804,836 |
| Industry | MED-DRUGS |
| Market Cap | 3.21 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.54 |
| PE (Forward) | 25.97 |
| Current Year Est. | 1.91 |
| Quarterly Earnings ESP |
4.00% |
Premium research
Zacks Rank
|
 2 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
88 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 25.97 |
| PEG Ratio | 0.85 |
| Current Year Est. | 1.91 |
| Current Quarter Estimate | 0.50 |
| Most Accurate Estimate | 0.52 |
| Earnings ESP |
4.00% |
| Next Earnings Report Date | 07-18-2013 |
| EPS Last Year | 2.08 |
| Expected Earnings Growth | 30.60% |
Company Description
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN, the first antibiotic in a new class of antiinfectives called lipopeptides. The Cubist product pipeline includes our lipopeptide program and our natural products screening program. Cubist is headquartered in Lexington, MA.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.50 | 0.50 | 1.91 | 2.48 |
| Number of Estimates | 14 | 15 | 13 | 13 |
| Low Estimate | 0.28 | 0.32 | 1.18 | 1.49 |
| High Estimate | 0.73 | 0.73 | 2.61 | NA |
| Year Ago EPS | 0.58 | 0.68 | 2.65 | 1.91 |
| EPS Growth | -13.05% | -27.06% | -28.07% | 30.27% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| CUBIST PHARM | CBST | 49.51 | |
|
| JAZZ PHARMACEUT | JAZZ | 58.36 | |
|
| SALIX PHARM-LTD | SLXP | 59.28 | |
|
| SANTARUS INC | SNTS | 21.91 | |
|
| USANA HLTH SCI | USNA | 65.46 | |
|
| BIOCRYST PHARMA | BCRX | 1.71 | |
|
| CATALYST PHARMA | CPRX | 0.83 | |
|
| CELL THERAPEUT | CTIC | 1.16 | |
|
| ELAN CP PLC ADR | ELN | 11.67 | |
|
| INFINITY PHARMA | INFI | 24.91 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Pipeline Progress at Gilead
May 16, 2013
Cempra/Toyama Ink Deal
May 15, 2013
Synergy Pharma Posts Wider Loss
May 15, 2013
Wider-Than-Expected Loss at Athersys
May 15, 2013
Celgene Attains 52-Week High
May 14, 2013
NPS Pharma Incurs Narrower 1Q Loss
May 14, 2013
Setback for Endo Health on Opana ER
May 13, 2013
Earnings Beat at Warner Chilcott
May 13, 2013
Financials
| EPS TTM | 2.08 |
| Sales | 926 |
| Net Income | 127 |
| Price/Earnings | 23.80 |
| Price/Book | 3.17 |
| Price/Cash Flow | 11.65 |
| Price/Sales | 3.40 |
News
Cubist Achieves Top Biotech Ranking in Globe 100 List - Businesswire
May 19, 2013
Benzinga`s M&A Chatter for Wednesday May 15, 2013 - Benzinga
May 15, 2013
Cubist Pharmaceuticals (CBST) Showing Bullish Technicals But Could Fall Through $48.02 Support - Freshbrewedmedia
May 15, 2013
Is AstraZeneca Gearing Up for a Shopping Spree? - TheMotleyFool
May 15, 2013
South African It Specialist Sees New Ways to Link Tech Projects - All Africa Global Media
May 14, 2013
Benzinga`s M&A Chatter for Monday May 13, 2013 - Benzinga
May 13, 2013
Shares of Cubist Pharmaceuticals Receive a Boost, Up 1.8% - Financial News Network Online - Market Movers
May 13, 2013
4 GARP Growers to Buy This Summer - TheStreet.com
May 10, 2013
Broker Recommendations
| Current ABR | 2.08 |
| ABR (Last Week) | 2.08 |
| # of recs in ABR | 18 |
| Average Target Price | 51.47 |
| Industry Rank by ABR | 88 out of 265 |
| Rank in Industry | 5 out of 91 |
